PTAB Will Review 2 Patents For Shire's ADHD Drug Mydayis
The Patent Trial and Appeal Board agreed Friday to review the entirety of two Shire PLC patents covering its long-acting attention deficit hyperactivity disorder medication Mydayis, following a challenge from KVK-Tech...To view the full article, register now.
Already a subscriber? Click here to view full article